Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06956079

Effect of End-inspiratory Pause on Gas Exchange During Mediastinal Mass Excision With CO2 Insufflation and One-lung Ventilation

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
58 (estimated)
Sponsor
Yonsei University · Academic / Other
Sex
All
Age
20 Years – 80 Years
Healthy volunteers
Not accepted

Summary

" Mediastinal mass excision is typically performed via video-assisted thoracoscopic surgery (VATS). To secure a clear surgical field, the ipsilateral lung must be deflated, achieved through one-lung ventilation (OLV) and intrathoracic CO₂ insufflation. However, OLV increases intrapulmonary shunt due to continued perfusion of the non-ventilated lung, potentially leading to hypoxemia and hypercapnia. When performed in the supine position, gas exchange becomes more challenging compared to lateral decubitus due to limited gravitational redistribution of blood flow. Although CO₂ insufflation aids surgical exposure through passive lung deflation, it may also increase CVP and PCWP, reduce cardiac output, and raise PaCO₂, contributing to respiratory acidosis. End-inspiratory pause (EIP), a ventilatory setting that pauses airflow at end-inspiration, prolongs alveolar gas exchange and improves ventilation-perfusion matching. Prior studies show EIP can enhance gas exchange, reduce microatelectasis, and improve CO₂ clearance in patients with acute lung injury. We therefore aimed to assess the effect of EIP application during VATS mediastinal mass excicion.

Conditions

Interventions

TypeNameDescription
PROCEDUREEIP-firstEIP is applied for 20 minutes immediately after the initiation of one-lung ventilation, followed by conventional mechanical ventilation.
PROCEDUREEIP-laterConventional mechanical ventilation is applied for 20 minutes after the initiation of one-lung ventilation, followed by EIP application.

Timeline

Start date
2025-05-01
Primary completion
2027-03-10
Completion
2027-03-10
First posted
2025-05-02
Last updated
2025-05-02

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT06956079. Inclusion in this directory is not an endorsement.